

1. DATE ISSUED MM/DD/YYYY 12/17/2019		1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA NO. 93.116 - Project Grants and Cooperative Agreements for Tuberculosis Control Programs			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 1 NU52PS910202-01-00 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NU52PS910202		5a. ACTION TYPE New	
6. PROJECT PERIOD MM/DD/YYYY From 01/01/2020		Through 12/31/2024	
7. BUDGET PERIOD MM/DD/YYYY From 01/01/2020		Through 12/31/2020	
8. TITLE OF PROJECT (OR PROGRAM) Tuberculosis Elimination and Laboratory in Missouri			

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention  
CDC Office of Financial Resources**

2939 Brandywine Road  
Atlanta, GA 30341

**NOTICE OF AWARD**  
AUTHORIZATION (Legislation/Regulations)  
[AWARD AUTHORITY NOT DEFINED FOR PS10-10136.NU2G]

9a. GRANTEE NAME AND ADDRESS  
HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF  
920 Wildwood Dr  
Health and Senior Services  
Jefferson City, MO 65109-5796

9b. GRANTEE PROJECT DIRECTOR  
Ms. Rachael Hahn  
920 Wildwood Drive  
Comm. Disease Control/Prevent  
Jefferson City, MO 65109-5796  
Phone: 573-751-6137

10a. GRANTEE AUTHORIZING OFFICIAL  
Ms. Tonya Loucks  
920 WILDWOOD DR  
JEFFERSON CITY, MO 65109-5796  
Phone: 000-000-0000

10b. FEDERAL PROJECT OFFICER  
Gail Grant  
1600 Clifton Rd  
Atlanta, GA 30333  
Phone: 404-639-8120

**ALL AMOUNTS ARE SHOWN IN USD**

<b>11. APPROVED BUDGET (Excludes Direct Assistance)</b>	
I Financial Assistance from the Federal Awarding Agency Only	<b>I</b>
II Total project costs including grant funds and all other financial participation	
a. Salaries and WageS .....	42,343.00
b. Fringe Benefits .....	25,406.00
c. Total Personnel Costs .....	67,749.00
d. Equipment .....	0.00
e. Supplies .....	3,981.00
f. Travel .....	4,807.00
g. Construction .....	0.00
h. Other .....	4,403.00
i. Contractual .....	67,574.00
j. TOTAL DIRECT COSTS	148,514.00
k. INDIRECT COSTS	14,498.00
<b>l. TOTAL APPROVED BUDGET</b>	<b>163,012.00</b>
m. Federal Share	163,012.00
n. Non-Federal Share	0.00

<b>12. AWARD COMPUTATION</b>	
a. Amount of Federal Financial Assistance (from item 11m)	163,012.00
b. Less Unobligated Balance From Prior Budget Periods	0.00
c. Less Cumulative Prior Award(s) This Budget Period	0.00
<b>d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION</b>	<b>163,012.00</b>
<b>13. Total Federal Funds Awarded to Date for Project Period</b>	<b>163,012.00</b>

<b>14. RECOMMENDED FUTURE SUPPORT</b> (Subject to the availability of funds and satisfactory progress of the project):			
YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
a. 2		d. 5	
b. 3		e. 6	
c. 4		f. 7	

**15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:**

<ul style="list-style-type: none"> <li>a. DEDUCTION</li> <li>b. ADDITIONAL COSTS</li> <li>c. MATCHING</li> <li>d. OTHER RESEARCH (Add / Deduct Option)</li> <li>e. OTHER (See REMARKS)</li> </ul>	<b>b</b>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------

**16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:**

- a. The grant program legislation
- b. The grant program regulations.
- c. This award notice including terms and conditions, if any, noted below under REMARKS.
- d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

**REMARKS** (Other Terms and Conditions Attached -  Yes  No)  
New Award: Financial Assistance in the amount of \$163,012

**GRANTS MANAGEMENT OFFICIAL:**

Arthur Lusby, Grants Management Officer, Team Lead  
2960 Brandywine Rd  
Mailstop TV-2  
Atlanta, GA 30341-5509  
Phone: 770.488.2865

17.OBJ CLASS	41.51	18a. VENDOR CODE		18b. EIN		19. DUNS	878092600	20. CONG. DIST.	03
FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION	
21. a.	0-9211183	b.	20NU52PS910202	c.	PS	d.	\$21,098.00	e.	75-20-0950
22. a.	0-9213485	b.	20NU52PS910202	c.	PS	d.	\$122,391.00	e.	75-20-0950
23. a.	0-9214095	b.	20NU52PS910202	c.	PS	d.	\$19,523.00	e.	75-20-0950

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 2	DATE ISSUED 12/17/2019
GRANT NO. 1 NU52PS910202-01-00	

**Direct Assistance**

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

# AWARD ATTACHMENTS

Missouri Department of Health

1 NU52PS910202-01-00

---

1. Terms & Conditions

**1 NU52PS910202-01-00**

**Missouri**

**AWARD INFORMATION**

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

<https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **PS20-2001**, entitled Tuberculosis Elimination and Laboratory Cooperative Agreement, and application dated **September 3, 2019**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$ 652,051** is approved for the Year 01 budget period, which is **January 1, 2020** through **December 31, 2020**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

**Available Funding:** The CDC is operating under a continuing resolution; as a result, the total available funding for the Fiscal Year (FY) **01** budget period is contingent upon the enactment of applicable appropriation bill(s). Funding in the amount of **\$ 163,012** in Financial Assistance (FA) is awarded 25% of the approved funding as listed for the component (s) below. The remainder of the budget period Approved Funding amount is subject to the availability of funds.

**P&C: \$ 135,757**

**HRD: \$ 6,157**

**LAB: \$ 21,098**

**Financial Assistance Mechanism:** Cooperative Agreement

***(Required Term for Cooperative Agreements) Substantial Involvement by CDC:*** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

**Prevention and Control (P&C)**

**CDC activities for this component are as follows:**

- Providing assistance with collaborative activities with other services and organizations (e.g., Centers of Excellence [COEs], private providers, community health centers [CHCs], federally qualified health centers [FQHCs]).
- Providing consultation through the CDC TB Health Equity Workgroup on initiating and maintaining activities to address health equity issues.
- Providing programmatic consultation and technical assistance in the development and implementation of new diagnostics and treatment services pertaining to TB control and prevention and to expand the reach of the population served.
- Providing technical assistance and consultation for empirical data collection in diverse settings to better define economic and epidemiologic context of TB control.
- Providing technical assistance to identify and notify areas about large outbreaks.
- Following up with programs to collect standardized public health information for clustered and non-genotyped cases and assess need for supplemental assistance.
- Collaborating with TB Program Evaluation Network (TB PEN) Steering Committee to incorporating any emerging, promising, and/or best practices to increase transparency, accountability, and adaption of these practices.
- Providing CDC or other subject matter expertise, technical assistance to assist recipient in areas requested such as surveillance, information technology, informatics, PE, program science approaches to strategy implementation, community engagement, and collaboration to advance program activities to achieve outcomes.
- Supporting and collaborating to compile and publish accomplishments, performance measures, and lessons learned during the project period.

### **Human Resource Development (HRD)**

#### **CDC activities for this component are as follows:**

- Providing technical assistance, as needed in assessing and prioritizing training and education needs and in planning, implementing, and evaluating training and education activities.
- Providing technical assistance as needed in developing a program-specific Training and Human Resource Development Plan; assistance can be provided in-person at the focal
- point meeting at the biennial TB ETN conference or via consultation with CDC after award of funds.
- Conducting a focal point meeting at the biennial TB ETN/TB PEN conference.
- Directing the COEs to coordinate regional on-site training courses (e.g., TB Contact Investigation Interviewing Skills course, Effective TB Interviewing for Contact Investigation course, or Program Managers course) in conjunction with designated focal points, and provide technical assistance as needed for development of program specific training activities.

### **Public Health Laboratory Strengthening**

#### **CDC activities for this component are as follows:**

- Contribute to the improvement of public health laboratory performance by providing technical assistance.

- Identify training needs and collaborate with partners to develop courses, webinars
- workshops, and training materials for distribution to public health laboratories.
- Provide consultation for the development and implementation of laboratory performance indicators and data analysis methods for laboratory internal quality assurance programs.
- Assist in the development and dissemination of best practice guidelines and recommendations for the implementation of cost-effective testing algorithms.
- Support laboratory performance evaluation by providing a biennial aggregate report of workload data and TAT performance measures from laboratories receiving funding assistance to be used to compare one's laboratory to national TB laboratory data.

**Direct Assistance (DA):** DA is awarded in the amount of for in this budget period.

**Summary/Technical Review Statement Response Requirement:** The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, February 3, 2020, will cause delay in programmatic progress and will adversely affect the future funding of this project.

**Expanded Authority:** The recipient [CHOOSE AN ITEM](#) permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

**Addition alternative:** Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

**Cost sharing or matching alternative:** Under this alternative, program income is used to finance some or the entire non-federal share of the project/program.

Note: The disposition of program income must have written prior approval from the GMO.

## FUNDING RESTRICTIONS AND LIMITATIONS

**Indirect Costs:** The recipient's indirect costs are approved and based on a de minimis rate of ten (10) percent of modified total direct costs (MTDC) as defined in 45 CFR Part 75.2, effective **SELECT DATE**.

Indirect costs are approved based on the negotiated indirect cost rate agreement dated **SELECT DATE**, which calculates indirect costs as follows, a **CHOOSE AN OPTION** is approved at a rate of **ENTER %** of the base, which includes, **ENTER TEXT**. The effective dates of this indirect cost rate are from **SELECT DATE** to **SELECT DATE**.

Indirect costs are based on the negotiated indirect cost rate agreement dated **SELECT DATE**. The rates in this agreement are to be used for the entire project period, including any approved extensions, in accordance with 45 CFR Part 75, Appendix III. Indirect cost/facilities and administration rates for subcontracts will be treated in the same manner as those for the recipient, if the subcontractor is covered by 45 CFR Part 75, Appendix III.

Indirect costs are approved based on the recipient's approved Cost Allocation Plan dated **SELECT DATE**.

Indirect costs are not approved for this award, because indirect costs were not requested or an approved Indirect Cost Rate Agreement has not been established. To have indirect costs approved for this grant, submit an approved indirect cost rate agreement to the grants management specialist no later than **SELECT DATE**.

Although **ENTER TEXT** has a negotiated indirect cost rate of **ENTER %** percent, a lower rate of **ENTER %** percent is requested. The reduced indirect cost rate is approved, with a base of **ENTER TEXT**.

Indirect costs are not applicable to this award.

#### **REPORTING REQUIREMENTS**

Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132** "Performance Progress and Monitoring Report" Expiration Date 8/31/2019. The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

#### **Required Disclosures for Federal Awardee Performance and Integrity Information System**

**(FAPIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Louvern Asante, Grants Management Officer/Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch 2920 Brandywine Road, MS E-15  
Atlanta, GA 30341  
Fax: N/A  
Email: [LHA5@cdc.gov](mailto:LHA5@cdc.gov) (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### **PROGRAM OR FUNDING GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

#### **PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

For additional information and/or to obtain your agency point of contact at the PMS, see, <https://pms.psc.gov/find-pms-liaison-accountant.html>

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.



The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

**Document Number:** XXXXXX

#### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**GMS Contact:**

Louvern Asante, Grants Management Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch  
2920 Brandywine Road, MS E-15  
Atlanta, GA 30341  
Telephone: (770) 488-3185  
Email: LHA5@cdc.gov

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**Programmatic Contact:**

Dawn Tuckey, Project Officer  
Centers for Disease Control and Prevention  
11 Corporate Blvd., MS E-10  
Atlanta, GA 30329-1902  
Telephone: 404-639-5323  
Fax: (404) 639-8308  
Email: dmt1@cdc.gov

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

**GMO Contact:**

Arthur C. Lusby, M.B.A.  
Grants Management Officer Centers for Disease Control and Prevention  
Infectious Diseases Services Branch  
2920 Brandywine Road, MS E-15  
Atlanta, GA 30341  
Telephone: (770) 488-2685 Email: ALusby@cdc.gov